Remove 2022 Remove Communication Remove Labelling
article thumbnail

RFID: The future of smart labelling?

Pharmaceutical Technology

In August of 2022, Fresenius Kabi announced a three-year plan to add GS1 Data Matrix barcodes, also known as 2D barcodes, to its US pharmaceutical portfolio. What lies ahead for RFID and smart labelling Volpe says “the future is bright” for smart technologies that identify, monitor, and track medications through the supply chain.

Labelling 105
article thumbnail

What They Said – Looking Back the First 6-Months of FDA Communications

Eye on FDA

You can see early in the chart, FDA maintained a very low volume of communications, and at mid-year in 2017 had issued only 52 releases, rising to 166 for the year. The current downturn in volume could also be attributable in part to the fact that FDA has once again altered somewhat a past communications practice.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA’s Revised Draft Guidance on Biological Product Promotion Provides Additional Recommendations/Clarifications

FDA Law Blog: Biosimilars

Promotional labeling is generally any labeling other than FDA-required labeling that is devised for the promotion of a product, as well as other functions, and can include printed, audio, or visual matter that describes the product. l)(1) (e.g.,

article thumbnail

EU antibiotic shortages being monitored by MSSG

European Pharmaceutical Review

Monitoring medicine shortages Since November 2022, MSSG and its working party, the Medicines Shortages Single Point of Contact (SPOC) working party, have been closely monitoring the EU antibiotic shortages. Manufacturing delays and production capacity issues have led to supply problems affecting the majority of Member States.

article thumbnail

It Finally Happened – FDA’s OPDP Issues First Letter of 2023

Eye on FDA

The last letter issued came just over a year ago in June, 2022. The label for the medicine includes a boxed warning regarding potential issues related to complications for the liver (toxicity) and heart (QT prolongation). The numbers plummet in 2014 until the record low last year of only 4 letters.

article thumbnail

New IFPMA and EFPIA guidance on use of social media by the pharmaceutical industry

pharmaphorum

The overarching principle set out in Codes of Practice, and in particular the Principles for the use of digital channels in the EFPIA Code , is that the legislation and Codes of Practice apply equally to communications by companies on social media and digital channels.

article thumbnail

FDA OPDP Look Back at 2021 – The Yawning Gap

Eye on FDA

As noted in the past, there are two primary means for understanding the agency’s latest thinking with respect to promotional communications from pharmaceutical companies – the content and pattern of enforcement and the issuance of guidance documents to shed light on the parameters that exist.